MARKET

IMMU

IMMU

Immunomedics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.28
-0.27
-1.46%
After Hours: 18.28 0 0.00% 16:36 01/24 EST
OPEN
18.55
PREV CLOSE
18.55
HIGH
18.80
LOW
17.79
VOLUME
1.98M
TURNOVER
--
52 WEEK HIGH
22.22
52 WEEK LOW
11.59
MARKET CAP
3.81B
P/E (TTM)
-12.1124
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IMMU and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

IMMU News

  • 7 Blockbuster Drugs Expected To Be Launched In 2020
  • Benzinga.6d ago
  • 7 Blockbuster Drugs Expected To Be Launched In 2020
  • Benzinga.6d ago
  • 3 “Strong Buy” Biotech Stocks That Can Inject a Healthy Dose of Upside
  • TipRanks.01/19 14:13
  • Immunomedics Sees Hammer Chart Pattern: Time to Buy?
  • Zacks.01/14 12:32

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About IMMU

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
More

Webull offers Immunomedics, Inc. (IMMU) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.